The treatment window can be extended to 4.5 hours for eligible patients.15,16 Use of intravenous alteplase is based on the landmark National Institute of Neurological Disorders and Stroke (NINDS) tPA trial which showed that patients who received tPA were at least 30% more likely to have minimal or no disability at 3 months on the assessment scales. The gene discussed is PLAT; the disease is Stroke.